<a id='d7a1926f-4bf1-48b8-80aa-2b94e2b6a0bb'></a>

AstraZeneca Pharma India Limited / Annual Report 2024-25

<a id='2b346123-659e-471f-bb24-e89e4d150bfa'></a>

<::logo: [Ubuntu] [Ubuntu] [A stylized circle with three smaller circles interconnected, forming a triangular shape, all in a shade of purple.]::>

<a id='31e7778b-1dde-4c51-aa24-13066ea70064'></a>

Balance Sheet

<a id='164457ea-c2d9-4093-aba6-a470f968718c'></a>

(All amounts in ₹ million, except per share and share data unless otherwise stated)
<table id="0-1">
<tr><td id="0-2"></td><td id="0-3">Note</td><td id="0-4">As at March 31, 2025</td><td id="0-5">As at March 31, 2024</td></tr>
<tr><td id="0-6">ASSETS</td><td id="0-7"></td><td id="0-8"></td><td id="0-9"></td></tr>
<tr><td id="0-a">Non-current assets</td><td id="0-b"></td><td id="0-c"></td><td id="0-d"></td></tr>
<tr><td id="0-e">Property, plant and equipment</td><td id="0-f">3A</td><td id="0-g">278.8</td><td id="0-h">603.7</td></tr>
<tr><td id="0-i">Right-of-use assets</td><td id="0-j">3A</td><td id="0-k">357.0</td><td id="0-l">42.0</td></tr>
<tr><td id="0-m">Capital work-in progress</td><td id="0-n">3A</td><td id="0-o">0.0</td><td id="0-p">2.7</td></tr>
<tr><td id="0-q">Intangible assets</td><td id="0-r">3B</td><td id="0-s">6.6</td><td id="0-t">21.1</td></tr>
<tr><td id="0-u">Financial assets</td><td id="0-v"></td><td id="0-w"></td><td id="0-x"></td></tr>
<tr><td id="0-y">Loans</td><td id="0-z">4</td><td id="0-A">1.1</td><td id="0-B">2.7</td></tr>
<tr><td id="0-C">Other financial assets</td><td id="0-D">5</td><td id="0-E">80.3</td><td id="0-F">24.7</td></tr>
<tr><td id="0-G">Current tax assets (net) (non-current)</td><td id="0-H">6</td><td id="0-I">602.6</td><td id="0-J">526.3</td></tr>
<tr><td id="0-K">Deferred tax assets (net)</td><td id="0-L">7</td><td id="0-M">415.6</td><td id="0-N">212.5</td></tr>
<tr><td id="0-O">Other non-current assets</td><td id="0-P">8</td><td id="0-Q">15.7</td><td id="0-R">17.5</td></tr>
<tr><td id="0-S">Total non-current assets</td><td id="0-T"></td><td id="0-U">1,757.7</td><td id="0-V">1,453.2</td></tr>
<tr><td id="0-W">Current assets</td><td id="0-X"></td><td id="0-Y"></td><td id="0-Z"></td></tr>
<tr><td id="0-10">Inventories</td><td id="0-11">9</td><td id="0-12">5,485.0</td><td id="0-13">2,278.8</td></tr>
<tr><td id="0-14">Financial assets</td><td id="0-15"></td><td id="0-16"></td><td id="0-17"></td></tr>
<tr><td id="0-18">Trade receivables</td><td id="0-19">10</td><td id="0-1a">1,848.8</td><td id="0-1b">1,531.3</td></tr>
<tr><td id="0-1c">Cash and cash equivalents</td><td id="0-1d">11</td><td id="0-1e">5,361.4</td><td id="0-1f">5,055.7</td></tr>
<tr><td id="0-1g">Bank balances other than cash and cash equivalents</td><td id="0-1h">12</td><td id="0-1i">5.6</td><td id="0-1j">2.7</td></tr>
<tr><td id="0-1k">Loans</td><td id="0-1l">4</td><td id="0-1m">3.0</td><td id="0-1n">1.3</td></tr>
<tr><td id="0-1o">Other financial assets</td><td id="0-1p">5</td><td id="0-1q">158.0</td><td id="0-1r">178.8</td></tr>
<tr><td id="0-1s">Other current assets</td><td id="0-1t">8</td><td id="0-1u">561.7</td><td id="0-1v">278.5</td></tr>
<tr><td id="0-1w">Total current assets</td><td id="0-1x"></td><td id="0-1y">13,423.5</td><td id="0-1z">9,327.1</td></tr>
<tr><td id="0-1A">Total assets</td><td id="0-1B"></td><td id="0-1C">15,181.2</td><td id="0-1D">10,780.3</td></tr>
<tr><td id="0-1E">EQUITY AND LIABILITIES</td><td id="0-1F"></td><td id="0-1G"></td><td id="0-1H"></td></tr>
<tr><td id="0-1I">Equity</td><td id="0-1J"></td><td id="0-1K"></td><td id="0-1L"></td></tr>
<tr><td id="0-1M">Equity share capital</td><td id="0-1N">13</td><td id="0-1O">50.0</td><td id="0-1P">50.0</td></tr>
<tr><td id="0-1Q">Other equity</td><td id="0-1R">14</td><td id="0-1S">7,653.5</td><td id="0-1T">7,069.2</td></tr>
<tr><td id="0-1U">Total equity</td><td id="0-1V"></td><td id="0-1W">7,703.5</td><td id="0-1X">7,119.2</td></tr>
<tr><td id="0-1Y">Liabilities</td><td id="0-1Z"></td><td id="0-20"></td><td id="0-21"></td></tr>
<tr><td id="0-22">Non-current liabilities</td><td id="0-23"></td><td id="0-24"></td><td id="0-25"></td></tr>
<tr><td id="0-26">Financial liabilities</td><td id="0-27"></td><td id="0-28"></td><td id="0-29"></td></tr>
<tr><td id="0-2a">Lease liabilities</td><td id="0-2b">17</td><td id="0-2c">294.5</td><td id="0-2d">27.8</td></tr>
<tr><td id="0-2e">Provisions</td><td id="0-2f">19</td><td id="0-2g">63.2</td><td id="0-2h">62.1</td></tr>
<tr><td id="0-2i">Other liabilities</td><td id="0-2j">18</td><td id="0-2k">90.0</td><td id="0-2l"></td></tr>
<tr><td id="0-2m">Total non-current liabilities</td><td id="0-2n"></td><td id="0-2o">447.7</td><td id="0-2p">89.9</td></tr>
<tr><td id="0-2q">Current liabilities</td><td id="0-2r"></td><td id="0-2s"></td><td id="0-2t"></td></tr>
<tr><td id="0-2u">Financial liabilities</td><td id="0-2v"></td><td id="0-2w"></td><td id="0-2x"></td></tr>
<tr><td id="0-2y">Lease liabilities</td><td id="0-2z">17</td><td id="0-2A">62.8</td><td id="0-2B">18.1</td></tr>
<tr><td id="0-2C">Trade payables</td><td id="0-2D"></td><td id="0-2E"></td><td id="0-2F"></td></tr>
<tr><td id="0-2G">Total outstanding dues of micro and small enterprises</td><td id="0-2H">15</td><td id="0-2I">25.3</td><td id="0-2J">36.1</td></tr>
<tr><td id="0-2K">Total outstanding dues of creditors other than micro and small enterprises</td><td id="0-2L">15</td><td id="0-2M">4,537.7</td><td id="0-2N">1,929.0</td></tr>
<tr><td id="0-2O">Other financial liabilities</td><td id="0-2P">16</td><td id="0-2Q">252.7</td><td id="0-2R">310.1</td></tr>
<tr><td id="0-2S">Provisions</td><td id="0-2T">19</td><td id="0-2U">1,065.3</td><td id="0-2V">434.2</td></tr>
<tr><td id="0-2W">Current tax liabilities (net)</td><td id="0-2X">20</td><td id="0-2Y">106.4</td><td id="0-2Z">66.6</td></tr>
<tr><td id="0-30">Other current liabilities</td><td id="0-31">18</td><td id="0-32">979.8</td><td id="0-33">777.1</td></tr>
<tr><td id="0-34">Total current liabilities</td><td id="0-35"></td><td id="0-36">7,030.0</td><td id="0-37">3,571.2</td></tr>
<tr><td id="0-38">Total liabilities</td><td id="0-39"></td><td id="0-3a">7,477.7</td><td id="0-3b">3,661.1</td></tr>
<tr><td id="0-3c">Total equity and liabilities</td><td id="0-3d"></td><td id="0-3e">15,181.2</td><td id="0-3f">10,780.3</td></tr>
</table>
The accompanying notes are an integral part of these Financial Statements.

<a id='62ad3655-fca1-41ac-8dc3-1cdb775f86ff'></a>

This is the Balance Sheet referred to in our report of even date.

<a id='42cd8fb1-495c-4d0a-bfcb-37c6d54b8b79'></a>

For Price Waterhouse & Co Chartered Accountants LLP
Firm registration number: 304026E/ E-300009

<a id='6dd4b077-2442-46fd-be36-8e31e043bc96'></a>

Sharmila Ramaswamy
Partner
Membership Number: 215131
Place: Bengaluru
Date: May 30, 2025

<a id='408ac8b3-e80e-4c3b-9765-fed5e60a9332'></a>

For and on behalf of the Board of Directors of
AstraZeneca Pharma India Limited
CIN: L24231KA1979PLC003563

<a id='6b566bc9-e431-4740-bf13-98239435c9fb'></a>

Shilpa Divekar Nirula
Chairperson
DIN: 06619353
Place: Mumbai
Date: May 30, 2025

<a id='14477f7b-2467-4d85-8987-91f99c9c2bf9'></a>

Manasa Rama
Company Secretary
Place: Bengaluru
Date: May 30, 2025

<a id='30c0f5d8-efc9-4581-83ab-ac337c2946fc'></a>

Sanjeev Kumar Panchal
Managing Director

DIN: 09823879
Place: Bengaluru
Date: May 30, 2025

<a id='aacddaac-b1aa-40d3-9ef9-0bbab09bfe14'></a>

Bhavana Agrawal
Director & Chief
Financial Officer
DIN: 10485441
Place: Bengaluru
Date: May 30, 2025

<a id='7eca353b-4ac8-4033-b1cc-5c272107b675'></a>

140

<!-- PAGE BREAK -->

<a id='974dbb06-a122-4f88-8700-fd891a479fdc'></a>

Corporate Overview | Statutory Reports / Financial Statements

<a id='8accbed8-6a55-4e6c-89ab-aa5b746cb6aa'></a>

Statement of Profit and Loss

<a id='f1a52ff9-d8f9-407c-a5e9-d4c88d1d86a0'></a>

(All amounts in ₹ million, except per share and share data unless otherwise stated)
<table id="1-1">
<tr><td id="1-2"></td><td id="1-3">Note</td><td id="1-4">For the year ended March 31, 2025</td><td id="1-5">For the year ended March 31, 2024</td></tr>
<tr><td id="1-6">Income</td><td id="1-7"></td><td id="1-8"></td><td id="1-9"></td></tr>
<tr><td id="1-a">Revenue from operations</td><td id="1-b">22</td><td id="1-c">17,162.9</td><td id="1-d">12,955.3</td></tr>
<tr><td id="1-e">Other income</td><td id="1-f">23</td><td id="1-g">406.3</td><td id="1-h">348.0</td></tr>
<tr><td id="1-i">Total income</td><td id="1-j"></td><td id="1-k">17,569.2</td><td id="1-l">13,303.3</td></tr>
<tr><td id="1-m">Expenses</td><td id="1-n"></td><td id="1-o"></td><td id="1-p"></td></tr>
<tr><td id="1-q">Cost of materials consumed</td><td id="1-r">24</td><td id="1-s">2,871.3</td><td id="1-t">1,290.2</td></tr>
<tr><td id="1-u">Purchase of Stock-in-Trade</td><td id="1-v">25</td><td id="1-w">10,088.2</td><td id="1-x">4,993.1</td></tr>
<tr><td id="1-y">Changes in inventories of finished goods, work-in-progress and stock-in-trade</td><td id="1-z">26</td><td id="1-A">(3,329.4)</td><td id="1-B">(337.7)</td></tr>
<tr><td id="1-C">Employee benefit expense</td><td id="1-D">27A</td><td id="1-E">2,574.4</td><td id="1-F">2,414.5</td></tr>
<tr><td id="1-G">Depreciation and amortisation expense</td><td id="1-H">28B</td><td id="1-I">399.9</td><td id="1-J">149.4</td></tr>
<tr><td id="1-K">Allowance for expected credit loss (net)</td><td id="1-L">38 (ii) (a)</td><td id="1-M">6.6</td><td id="1-N">54.4</td></tr>
<tr><td id="1-O">Other expenses</td><td id="1-P">28A</td><td id="1-Q">2,412.1</td><td id="1-R">2,696.3</td></tr>
<tr><td id="1-S">Finance costs</td><td id="1-T">29</td><td id="1-U">14.6</td><td id="1-V">12.0</td></tr>
<tr><td id="1-W">Total expenses</td><td id="1-X"></td><td id="1-Y">15,037.7</td><td id="1-Z">11,272.2</td></tr>
<tr><td id="1-10">Profit before exceptional items and tax</td><td id="1-11"></td><td id="1-12">2,531.5</td><td id="1-13">2,031.1</td></tr>
<tr><td id="1-14">Add/(Less): Exceptional Items</td><td id="1-15">27B</td><td id="1-16">(967.9)</td><td id="1-17">164.3</td></tr>
<tr><td id="1-18">Profit before tax</td><td id="1-19"></td><td id="1-1a">1,563.6</td><td id="1-1b">2,195.4</td></tr>
<tr><td id="1-1c">Tax expense</td><td id="1-1d"></td><td id="1-1e"></td><td id="1-1f"></td></tr>
<tr><td id="1-1g">Current tax</td><td id="1-1h">21</td><td id="1-1i">601.0</td><td id="1-1j">535.5</td></tr>
<tr><td id="1-1k">Tax provision relating to prior year</td><td id="1-1l">21</td><td id="1-1m">4.4</td><td id="1-1n">53.8</td></tr>
<tr><td id="1-1o">Deferred tax credit</td><td id="1-1p">21</td><td id="1-1q">(199.2)</td><td id="1-1r">(9.0)</td></tr>
<tr><td id="1-1s">Total tax expense</td><td id="1-1t"></td><td id="1-1u">406.2</td><td id="1-1v">580.3</td></tr>
<tr><td id="1-1w">Profit for the year</td><td id="1-1x"></td><td id="1-1y">1,157.4</td><td id="1-1z">1,615.1</td></tr>
<tr><td id="1-1A">Other comprehensive income/ (loss)</td><td id="1-1B"></td><td id="1-1C"></td><td id="1-1D"></td></tr>
<tr><td id="1-1E">Items that will not be reclassified to profit or loss</td><td id="1-1F"></td><td id="1-1G"></td><td id="1-1H"></td></tr>
<tr><td id="1-1I">Re-measurement gains/(losses) on post employment benefit obligations</td><td id="1-1J">35 (ii)(C)(e)</td><td id="1-1K">(15.6)</td><td id="1-1L">13.3</td></tr>
<tr><td id="1-1M">Income tax effect on above</td><td id="1-1N">7</td><td id="1-1O">3.9</td><td id="1-1P">(3.3)</td></tr>
<tr><td id="1-1Q">Other comprehensive income/ (loss) for the year, net of tax</td><td id="1-1R"></td><td id="1-1S">(11.7)</td><td id="1-1T">10.0</td></tr>
<tr><td id="1-1U">Total comprehensive income for the year</td><td id="1-1V"></td><td id="1-1W">1,145.7</td><td id="1-1X">1,625.1</td></tr>
<tr><td id="1-1Y">Earnings per equity share (equity shares, par value of ₹ 2 each)</td><td id="1-1Z"></td><td id="1-20"></td><td id="1-21"></td></tr>
<tr><td id="1-22">-Basic and diluted</td><td id="1-23">30</td><td id="1-24">46.3</td><td id="1-25">64.6</td></tr>
</table>

<a id='a893bf99-f3b8-46fe-8141-2da8ae1c1aba'></a>

The accompanying notes are an integral part of these Financial Statements.

<a id='e196748c-343a-4eeb-824a-9dfc826782fa'></a>

This is the Statement of Profit and Loss referred to in our report of even date.

<a id='ca94f302-f7ea-435f-9088-aee0a999fabc'></a>

For Price Waterhouse & Co Chartered Accountants LLP
Firm registration number: 304026E/ E-300009

<a id='4a8e44e2-d355-4f35-8739-a3e542f98db8'></a>

For and on behalf of the Board of Directors of
AstraZeneca Pharma India Limited
CIN: L24231KA1979PLC003563

<a id='d41872f6-7118-44fb-8e6f-ec7863378f45'></a>

Sharmila Ramaswamy
Partner
Membership Number: 215131
Place: Bengaluru
Date: May 30, 2025

<a id='4a45a311-c429-4870-b2b6-81bc1a6b84d0'></a>

Shilpa Divekar Nirula
Chairperson
DIN: 06619353
Place: Mumbai
Date: May 30, 2025

<a id='f0753dcb-431e-4008-b506-5824675f1501'></a>

Sanjeev Kumar Panchal
Managing Director
DIN: 09823879
Place: Bengaluru
Date: May 30, 2025

<a id='3783fe0e-f88c-4c2b-a7f8-869d37084323'></a>

Manasa Rama
Company Secretary

Place: Bengaluru
Date: May 30, 2025

<a id='3b87eae6-a352-4528-935c-f47a331111ce'></a>

Bhavana Agrawal
Director & Chief
Financial Officer
DIN: 10485441
Place: Bengaluru
Date: May 30, 2025

<a id='90a61c9a-9fbf-45ef-b1af-c28842a5316c'></a>

141 /

<!-- PAGE BREAK -->

<a id='09f74e72-0583-4e61-a86d-6a840f937c1c'></a>

AstraZeneca Pharma India Limited Annual Report 2024-25

<a id='f1ca60e8-5c86-4953-b316-c48cb9270f1d'></a>

<::logo: [Ubuntu] 
 A stylized purple circle is surrounded by three smaller, connected circles, forming a triangular shape.::>

<a id='19ee42e8-b6bf-420f-838a-84315fe4cb53'></a>

Statement of cash flows

<a id='618c748d-118c-4531-b5ae-41cbb987be83'></a>

(All amounts in ₹ million, except per share and share data unless otherwise stated)
<table id="4-1">
<tr><td id="4-2"></td><td id="4-3">Note</td><td id="4-4">For the year ended March 31, 2025</td><td id="4-5">For the year ended March 31, 2024</td></tr>
<tr><td id="4-6">D) Net increase in cash and cash equivalents (A+B+C)</td><td id="4-7"></td><td id="4-8">305.7</td><td id="4-9">52.3</td></tr>
<tr><td id="4-a">E) Cash and cash equivalents at the beginning of the year</td><td id="4-b"></td><td id="4-c">5,055.7</td><td id="4-d">5,003.4</td></tr>
<tr><td id="4-e">F) Cash and cash equivalents at the end of the year</td><td id="4-f"></td><td id="4-g">5,361.4</td><td id="4-h">5,055.7</td></tr>
<tr><td id="4-i">Non-cash financing and investing activities</td><td id="4-j"></td><td id="4-k"></td><td id="4-l"></td></tr>
<tr><td id="4-m">- Acquisition of right-of-use assets</td><td id="4-n"></td><td id="4-o">365.3</td><td id="4-p">12.4</td></tr>
</table>

<a id='d8794018-4142-4268-8453-597d76a88d51'></a>

Components of cash and cash equivalents as at the end of the year
<table id="4-q">
<tr><td id="4-r"></td><td id="4-s"></td><td id="4-t">As at March 31, 2025</td><td id="4-u">As at March 31, 2024</td></tr>
<tr><td id="4-v">Balance with banks :</td><td id="4-w"></td><td id="4-x"></td><td id="4-y"></td></tr>
<tr><td id="4-z">Current accounts</td><td id="4-A">11</td><td id="4-B">268.1</td><td id="4-C">188.7</td></tr>
<tr><td id="4-D">Demand deposits with original maturity of less than 3 months</td><td id="4-E">11</td><td id="4-F">5,093.3</td><td id="4-G">4,867.0</td></tr>
<tr><td id="4-H">Total cash and cash equivalents</td><td id="4-I"></td><td id="4-J">5,361.4</td><td id="4-K">5,055.7</td></tr>
</table>

<a id='11b66c92-09c0-48b3-bc1e-17d2fe536b3f'></a>

Note: The Statement of cash flows has been prepared under the "Indirect Method" as set out in Ind AS 7 on Statement of cash flows as notified under Companies (Accounts) Rules, 2015.

<a id='a6c12dc7-e56e-4dbd-838f-84e65dfb62a2'></a>

The accompanying notes are an integral part of these Financial Statements.

<a id='1424eec8-45df-4fc1-acbc-5cee454ed8fd'></a>

This is the Statement of cash flows referred to in our report of even date.

<a id='22367661-adbb-40fa-97d2-125dc2c73f7b'></a>

For Price Waterhouse & Co Chartered Accountants LLP
Firm registration number: 304026E/ E-300009

<a id='b38a4833-cc6f-41b1-b378-d421d1f8f069'></a>

Sharmila Ramaswamy
Partner
Membership Number: 215131
Place: Bengaluru
Date: May 30, 2025

<a id='60a736c9-3dc3-4761-a5a1-f349237c9b12'></a>

For and on behalf of the Board of Directors of
AstraZeneca Pharma India Limited
CIN:
L24231KA1979PLC003563

<a id='d95cfa08-2af3-4807-97d7-5cf80d7c82a7'></a>

Shilpa Divekar Nirula
Chairperson

DIN: 06619353
Place: Mumbai
Date: May 30, 2025

<a id='41a5382d-5f6e-49dd-a783-98346b376d94'></a>

Sanjeev Kumar Panchal
Managing Director
DIN: 09823879
Place: Bengaluru
Date: May 30, 2025

<a id='61c24193-1506-49b9-a642-7beba060930f'></a>

**Manasa Rama**
Company Secretary
Place: Bengaluru
Date: May 30, 2025

<a id='ae6aed26-940b-49cc-bda7-68f92bbd6876'></a>

Bhavana Agrawal
Director & Chief
Financial Officer

DIN: 10485441

Place: Bengaluru

Date: May 30, 2025

<a id='f1d353a1-b862-4cdb-9992-34c657143f56'></a>

/ 144